Article Text

A short and intensive single-agent cisplatin regimen for recurrent carcinoma of the uterine cervix
  1. M. Daly*,
  2. V. J. Cowie,
  3. J. A. Davis,
  4. T. Habeshaw*,
  5. E.J. Junor*,
  6. J. Paul*,
  7. E. Pyper*,
  8. N.S. Reed*,
  9. M. Soukop§,
  10. H. Yosef* and
  11. R.P. Symonds*
  1. * Beatson Oncology Centre, Western Infirmary, Glasgow;†Department of Clinical Oncology, Western General Hospital, Edinburgh; ‡Department of Gynecology, Stobhill Hospital, Glasgow; and §Department of Medical Oncology, Royal Infirmary, Glasgow, UK
  1. Address for correspondence: Dr M. Daly, Senior Registrar in Clinical Oncology, Beatson Oncology Centre, Dumbarton Road, Glasgow G11 6NT, UK.

Abstract

Between May 1991 and September 1993, 36 patients with recurrent carcinoma of the uterine cervix were treated with single-agent cisplatin using an intensive regimen of four weekly cycles of 50 mg m-2 followed in responders by a further four cycles given every fortnight. The response rate was 47% (95%CI: 27-66%), 56% in those with pelvic recurrence, and 38% in those with metastatic disease. All responses but one were seen within 4 weeks of commencing treatment. Three patients (9%) had a complete response, although in two cases this was of short duration. The treatment was moderately well tolerated and the principle toxicities were myelotoxicity and emesis. The median survival was 32 weeks, and the 18-month survival was 13%.

This regimen gives a response rate similar to that seen with more toxic combination chemotherapy regimens such as BIP (bleomycin, ifosfamide and cisplatin). It has the particular advantages of a short duration of treatment and early response, allowing treatment to be stopped after 4 weeks in non-responders. The response rate in pelvic recurrence was better than that seen in most previous chemotherapy trials, particularly as 78% of the evaluable patients with pelvic recurrence had previously received radical radiotherapy to the pelvis.

Weekly, followed by fortnightly cisplatin, is an appropriate palliative treatment for patients with recurrent carcinoma of the uterine cervix for whom chemotherapy is indicated.

  • carcinoma
  • cisplatin
  • intensive chemotherapy
  • uterine cervix

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.